2025-04-02 12:33:09
Latest Post
GAIL opens fresh round of inviting proposals for equity investment in Start-Ups
NRF expands production capacity with new factory of 11900m2 in Poland
Tata Communications a Leader for 12th consecutive year in Gartner Magic Quadrant
Bharti Airtel and Nokia expand core network collaboration to speed-up new 5G service delivery
Emerald Finance infuses ₹10 Cr with Preferential Allotment of Equity Shares to Promoters, FIIs and HNIs
Stock Report
Suven Pharmaceuticals Ltd reports consolidated PAT of Rs. 72.05 crores in Q2FY23
Posted On : 2022-11-08 13:00:44( TIMEZONE : IST )
Suven Pharmaceuticals Limited has reported Consolidated financial results for the period ended September 30, 2022.
Financial Results (Q2 FY2023) - QoQ Comparison
The company has reported total income of Rs. 289.3218 crores during the period ended September 30, 2022 as compared to Rs. 349.8322 crores during the period ended June 30, 2022.
The company has posted net profit / (loss) of Rs. 72.0563 crores for the period ended September 30, 2022 as against net profit / (loss) of Rs. 107.5421 crores for the period ended June 30, 2022.
The company has reported EPS of Rs. 2.83 for the period ended September 30, 2022 as compared to Rs. 4.22 for the period ended June 30, 2022.
| Financials | Q2 FY2023 | Q1 FY2023 | % Change |
| Total Income | ₹ 289.3218 crs | ₹349.8322 crs |  -17.30% |
| Net Profit | ₹72.0563 crs | ₹107.5421 crs | -33.00% |
| EPS | ₹2.83 | ₹4.22 | -32.94% |
Financial Results (Q2 FY2023) - YoY Comparison
The company has reported total income of Rs. 289.3218 crores during the period ended September 30, 2022 as compared to Rs.306.0294 crores during the period ended September 30, 2021.
The company has posted net profit / (loss) of Rs.72.0563 crores for the period ended September 30, 2022 as against net profit / (loss) of Rs.96.9848 crores for the period ended September 30, 2021.
The company has reported EPS of Rs.2.83 for the period ended September 30, 2022 as compared to Rs.3.81 for the period ended September 30, 2021.
| Financials | Q2 FY2023 | Q2 FY2022 | % Change |
| Total Income | ₹ 289.3218 crs | ₹306.0294 crs | -5.46% |
| Net Profit | ₹72.0563 crs | ₹96.9848 crs | -25.70% |
| EPS | ₹2.83 | ₹3.81 | -25.72% |
Financial Results (Half Year Ended FY2023) - YoY Comparison
The company has reported total income of Rs.639.1540 crores during the 6 Months period ended September 30, 2022 as compared to Rs.575.6136 crores during the 6 Months period ended September 30, 2021.
The company has posted net profit / (loss) of Rs.179.5984 crores for the 6 Months period ended September 30, 2022 as against net profit / (loss) of Rs.202.0679 crores for the 6 Months period ended September 30, 2021.
The company has reported EPS of Rs.7.06 for the 6 Months period ended September 30, 2022 as compared to Rs.7.94 for the 6 Months period ended September 30, 2021.
| Financials | Half Year Ended FY2023 | Half Year Ended FY2022 | % Change |
| Total Income | ₹639.1540 crs | ₹575.6136 crs |  11.04% |
| Net Profit | ₹179.5984 crs | ₹202.0679 crs | -11.12% |
| EPS | ₹7.06 | ₹7.94 | -11.08% |
Shares of Suven Pharmaceuticals Limited was last trading in BSE at Rs. 439.90 as compared to the previous close of Rs. 428.30. The total number of shares traded during the day was 48477 in over 2613 trades.
The stock hit an intraday high of Rs. 445.00 and intraday low of 426.00. The net turnover during the day was Rs. 21152306.00.
